Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma

Cancer Treatment Reviews · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles